H2O2-Activatable Boronic Esters for Targeted Antioxidant Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for oxidative stress-related injuries, such as ischemia/reperfusion injury, are limited by the non-specific suppression of reactive oxygen species (ROS), which can lead to undesirable side effects and inadequate therapeutic benefits, as they fail to target the site of oxidative stress effectively.
Innovation Solution
Development of hydrogen peroxide (H2O2)-activatable 4-(hydroxymethyl)phenylboronic esters that specifically react with high H2O2 levels to release 4-hydroxybenzyl alcohol (HBA), providing targeted anti-oxidant and anti-inflammatory effects while sparing normal physiological H2O2 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific antioxidant therapy is used to suppress ROS, then oxidative stress is reduced, but side effects increase and therapeutic benefits are inadequate due to failure to target the site of oxidative stress
Solution Approach 1:
The patent applies local quality by designing H2O2-activatable prodrugs that selectively release antioxidant compounds only at sites with high H2O2 concentrations (pathological conditions), while remaining inactive in normal tissues. This spatially differentiated activation ensures therapeutic efficacy at the target site without affecting other physiological processes, thereby reducing side effects while maintaining therapeutic benefit.
Solution Approach 2:
The patent uses H2O2-activatable prodrugs as intermediaries that bridge the gap between systemic administration and localized action. The prodrug molecules circulate systemically but remain inactive until they encounter high H2O2 levels at the pathological site, where they are activated to release the active antioxidant compound. This intermediary mechanism enables targeted delivery without requiring direct localization methods.
2Object-affected harmful factors
If H2O2-activatable prodrugs are used to achieve targeted therapy, then specificity increases and side effects decrease, but the complexity of the drug delivery system increases
Solution Approach 1:
The patent employs parameter changes by utilizing the concentration-dependent activation property of H2O2-activatable prodrugs. The prodrugs remain chemically stable at normal H2O2 levels but undergo rapid hydrolysis at high H2O2 concentrations. This parameter-based activation mechanism (switching from stable to reactive state based on H2O2 concentration) provides a simple yet effective way to achieve targeted release without complex delivery systems.
Solution Approach 2:
The H2O2-activatable prodrugs exhibit self-service characteristics by automatically activating and releasing the active compound in response to the local H2O2 environment. The prodrug molecules themselves contain the activation mechanism (boronic ester or disulfide bonds that are cleaved by H2O2), eliminating the need for external activation systems or complex delivery vehicles. The therapeutic agent self-regulates its release based on the pathological condition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The H2O2-activatable boronic esters effectively reduce oxidative stress and inflammation, minimizing tissue damage and improving outcomes in conditions like cardiac and hepatic ischemia/reperfusion injuries by selectively scavenging H2O2 and releasing HBA, thereby reducing apoptosis and inflammation.
Implementation Method 1
H2O2-activatable 4-(hydroxymethyl)phenylboronic esters that specifically react with high H2O2 levels to release 4-hydroxybenzyl alcohol (HBA)
Data Source
AI summary
The present invention includes 4-(hydroxymethyl)phenylboronic esters, which react with hydrogen peroxide to form 4-hydroxybenzyl alcohol, which is an anti-inflammatory and/or anti-oxidant compound, as well as microparticles and compositions thereof. In certain embodiments, the compositions of the invention may be used to treat or prevent oxidative stress and/or inflammation, including ischemic disease.